Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions.

Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pöllinger B, Schnell C, Hiestand PC.

J Neuroinflammation. 2010 Dec 22;7:95. doi: 10.1186/1742-2094-7-95.

2.

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.

Irie O, Kosaka T, Kishida M, Sakaki J, Masuya K, Konishi K, Yokokawa F, Ehara T, Iwasaki A, Iwaki Y, Hitomi Y, Toyao A, Gunji H, Teno N, Iwasaki G, Hirao H, Kanazawa T, Tanabe K, Hiestand PC, Malcangio M, Fox AJ, Bevan SJ, Yaqoob M, Culshaw AJ, Hart TW, Hallett A.

Bioorg Med Chem Lett. 2008 Oct 1;18(19):5280-4. doi: 10.1016/j.bmcl.2008.08.067. Epub 2008 Aug 22.

PMID:
18783943
3.

Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.

Hiestand PC, Rausch M, Meier DP, Foster CA.

Prog Drug Res. 2008;66:361, 363-81. Review.

PMID:
18416311
4.

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.

Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA.

Brain Res Bull. 2007 Oct 19;74(5):307-16. Epub 2007 Jul 30.

PMID:
17845905
5.

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.

Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A.

J Pharmacol Exp Ther. 2007 Nov;323(2):469-75. Epub 2007 Aug 6.

PMID:
17682127
6.

Immunomodulation: particular perspectives.

Borel JF, Hiestand PC.

Transplant Proc. 1999 May;31(3):1464-71. Review. No abstract available.

PMID:
10330972
7.

Pharmacological studies with Norvaline2-cyclosporine (SDZ OG 37-325) in comparison with cyclosporine (Sandimmun): a summary.

Hiestand PC, Traber R, Borel JF.

Transplant Proc. 1994 Oct;26(5):2999-3001. Review. No abstract available.

PMID:
7940947
8.

New cyclosporine derivative SDZ IMM 125: in vitro and in vivo pharmacologic effects and toxicologic evaluation.

Hiestand PC, Gräber M, Hurtenbach U, Herrmann P, Cammisuli S, Richardson BP, Eberle MK, Donatsch P, Ryffel B, Borel JF.

Transplant Proc. 1993 Feb;25(1 Pt 1):691-2. Review. No abstract available.

PMID:
8438439
9.

The new cyclosporine derivative, SDZ IMM 125: in vitro and in vivo pharmacologic effects.

Hiestand PC, Gräber M, Hurtenbach U, Herrmann P, Cammisuli S, Richardson BP, Eberle MK, Borel JF.

Transplant Proc. 1992 Aug;24(4 Suppl 2):31-8. No abstract available.

PMID:
1386701
10.

Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.

Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC.

Int J Cancer. 1992 May 28;51(3):433-8.

PMID:
1534319
11.

SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.

Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, Hiestand PC.

Int J Cancer. 1992 Feb 20;50(4):593-7.

PMID:
1347037
12.

Identification of several cyclosporine binding proteins in lymphoid and non-lymphoid cells in vivo.

Foxwell BM, Woerly G, Husi H, Mackie A, Quesniaux VF, Hiestand PC, Wenger RM, Ryffel B.

Biochim Biophys Acta. 1992 Feb 14;1138(2):115-21.

PMID:
1540657
13.

FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae.

Heitman J, Movva NR, Hiestand PC, Hall MN.

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1948-52.

14.

Yeast cyclophilin: isolation and characterization of the protein, cDNA and gene.

Haendler B, Keller R, Hiestand PC, Kocher HP, Wegmann G, Movva NR.

Gene. 1989 Nov 15;83(1):39-46.

PMID:
2687115
15.
16.

Molecular characteristics of cyclophilin-cyclosporine interaction.

Quesniaux VF, Schreier MH, Wenger RM, Hiestand PC, Harding MW, Van Regenmortel MH.

Transplantation. 1988 Aug;46(2 Suppl):23S-28S.

PMID:
2970139
17.

Cyclosporine A and cyclosporine G enhance IgG rheumatoid factor production in MRL/lpr mice.

Gunn HC, Hiestand PC.

Transplant Proc. 1988 Jun;20(3 Suppl 4):238-42. No abstract available.

PMID:
3260051
18.

Cyclosporine-cyclophilin interaction.

Quesniaux VF, Schreier MH, Wenger RM, Hiestand PC, Van Regenmortel MH.

Transplant Proc. 1988 Apr;20(2 Suppl 2):58-62. No abstract available.

PMID:
3284106
19.

Ciclosporin treatment in experimental autoimmune myasthenia gravis.

Gunn HC, Hiestand PC, Hanglow AC.

Monogr Allergy. 1988;25:96-107. No abstract available.

PMID:
3262820
20.

Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity.

Quesniaux VF, Schreier MH, Wenger RM, Hiestand PC, Harding MW, Van Regenmortel MH.

Eur J Immunol. 1987 Sep;17(9):1359-65.

PMID:
3308488
21.

Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine.

Hiestand PC, Mekler P, Nordmann R, Grieder A, Permmongkol C.

Proc Natl Acad Sci U S A. 1986 Apr;83(8):2599-603.

22.

Mechanism of action: ciclosporin- and prolactin-mediated control of immunity.

Hiestand PC, Mekler P.

Prog Allergy. 1986;38:239-46. No abstract available.

PMID:
3014546
23.

Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydro-cyclosporine.

Hiestand PC, Gunn HC, Gale JM, Ryffel B, Borel JF.

Immunology. 1985 Jun;55(2):249-55.

24.

Immunostimulatory properties of ethylene-2,2' -bis(dithio)bis(ethanol) and related compounds in vivo.

Hiestand PC, Strasser M.

Int J Immunopharmacol. 1985;7(1):141-51.

PMID:
3888866
26.
27.
29.

Dispholidus typus (bommslang) snake venom: purification and properties of the coagulant principle.

Hiestand PC, Hiestand RR.

Toxicon. 1979;17(5):489-98. No abstract available.

PMID:
516082
30.

The effects of fractions (chalones) obtained from lymphoid organs on the immune response in vivo.

Borel JF, Feurer C, Hiestand PC, Stähelin H.

Agents Actions. 1978 Oct;8(5):523-31.

PMID:
31079
31.

The effects of fractions (chalones) obtained from lymphoid organs on lymphocyte proliferation in vitro.

Hiestand PC, Borel JF, Bauer W, Kis ZL, Magnée C, Stähelin H.

Agents Actions. 1977 Sep;7(3):327-35.

PMID:
145797
32.

Adenosine 3':5'-monophosphate-dependent protein kinase and the stimulation of ovarian nuclear ribonucleic acid polymerase activities.

Jungmann RA, Hiestand PC, Schweppe JS.

J Biol Chem. 1974 Sep 10;249(17):5444-51. No abstract available.

34.

Mechanism of action of gonadotropin. 3. Binding of adenosine 3',5'-monophosphate by the 105,000 X g supernatant fraction from homogenates of calf ovaries.

Hiestand PC, Eppenberger U, Jungmann RA.

Endocrinology. 1973 Jul;93(1):217-30. No abstract available.

PMID:
4351314

Supplemental Content

Loading ...
Support Center